Back to top
more

Merrimack Pharmaceuticals, Inc. (MACK)

(Delayed Data from NSDQ)

$5.90 USD

5.90
90,880

+0.05 (0.85%)

Updated May 3, 2019 03:59 PM ET

After-Market: $5.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up

Merrimack (MACK) reported narrower-than-expected loss in the third quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

    Merrimack's (MACK) Reports Narrower-than-Expected Q3 Loss

    Merrimack Pharmaceuticals (MACK) announced third quarter results with loss narrower than expected, however, revenues misses the same.

      What's in the Cards for Merrimack (MACK) in Q3 Earnings?

      Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

        Merrimack (MACK) Q2 Loss Wider than Expected, Stock Falls

        Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.

          Merrimack's (MACK) Reports Wider-than-Expected Q2 Loss

          Merrimack Pharmaceuticals (MACK) announced second-quarter results, reporting a wider than expected loss of 22 cents per share.

            What's in the Cards for Merrimack (MACK) in Q2 Earnings?

            Sales of Merrimack Pharmaceuticals, Inc???s (MACK) only approved product, Onivyde to Ipsen is expected to bring in $450 million this quarter.

              Merrimack Completes Enrollment in Phase II Study for MM-141

              Merrimack Pharmaceuticals announced completion of enrollment in the ongoing phase II study, evaluatingMM-141 in combination with standard of care for treatment of patients with previously untreated metastatic pancreatic cancer.

                Why Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report?

                Merrimack (MACK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Merrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde

                  Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 22 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents. The company had reported a loss of 32 cents in the year-ago quarter.

                    Indrajit Bandyopadhyay headshot

                    Merrimack's (MACK) Reports Wider-than-Expected Q1 Loss

                    Merrimack reported a wider than expected first-quarter loss. The company reported a loss of 22 cents per share, wider than our consensus estimate of 7 cents.

                      What's in the Cards for Merrimack (MACK) in Q1 Earnings?

                      Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations

                        Are Options Traders Betting on a Big Move in Merrimack (MACK) Stock?

                        Options traders are pricing in a big move for Merrimack (MACK) shares as it has huge implied volatility.

                          Merrimack (MACK) Starts Enrollment in Solid Tumors Study

                          Merrimack Pharmaceuticals, Inc. (MACK) announced that it has enrolled the first patient in a phase I study on MM-310 for solid tumors.

                            Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top

                            Merrimack Pharmaceuticals, Inc. (MACK) reported a loss of 21 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate of a loss of 22 cents.

                              Ekta Bagri headshot

                              Merrimack's (MACK) Q4 Loss In-Line With Estimates

                              Merrimack (MACK) reported a fourth-quarter loss in-line with the estimates.

                                Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

                                Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

                                  Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?

                                  Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.

                                    Is the Options Market Predicting a Spike in Merrimack (MACK) Stock?

                                    Options traders are pricing in a big move for Merrimack (MACK) shares as it has huge implied volatility.

                                      Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B

                                      Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.

                                        Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops

                                        Shares of Merrimack Pharmaceuticals, Inc. (MACK) tanked 18.4% after the company announced the discontinuation of a phase II trial on its breast cancer candidate, MM-302.

                                          Tracey Ryniec headshot

                                          How to Find Winning Biotech Stocks

                                          The biotechs are a gamble but here are some guidelines to lessen the risk.